



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE TEAMS MEETING 19th July 2023

PRESENT:

Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL ICB
Dr S Ramtoola (SR)	Consultant Physician, ELHT (Chairperson)
Mr J Vaughan (JV)	Senior Medicines Commissioning Pharmacist NHS EL/BwD ICB
Ms Ana Batista (AB)	Medicines Information Pharmacist ELHT
Dr S Jackson (SJ)	GPwSI in therapeutics
Mrs H Robinson (HR)	Divisional Lead Pharmacist – MEC
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT

IN ATTENDANCE:

Miss E Bland (EB)	Obs & Gynaecology Directorate Pharmacist
Dr A Daly (AD)	Consultant in Restorative Dentistry
Mr N Charaklias (NC)	ENT Consultant
Mr W Price (WP)	Specialist Pharmacist for Dermatology
Mr J Husain	ELHT Executive Medical Director
Mr M Gill	Consultant Colorectal Surgeon

2023/90: APOLOGIES:

Mr U Akram (UA)	Deputy Lead Pharmacist, LS CFT
Ms L Prince (LP)	Senior Medicines Management Technician, EL ICB
Dr F Shah (FS)	GP/Consultant MFOP & Diabetes
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Mr C Woods (CW)	Head of Contracting and Costing, Finance

2023/91: DECLARATION OF INTEREST

None declared.

2023/92: MINUTES OF JUNE TEAMS MEETING:

Accepted as accurate record.

2023/93: MATTERS ARISING:

2021/101b/ 2023/09: ELMMB Membership – to remain on action matrix as a standing item for feedback.

ELMMB meetings: ToR to be reviewed – the group feel there is value in retaining the established working relationships but need to define the roles and responsibilities of the group.



ACTION: LR/JV to revisit ToR.

2023/26: GLT2i dosing considerations according to eGFR when treating T2D, HF or CKD – Updated version.

Resolved: The revised version is much easier to understand and will be a really useful reference for clinicians. Accepted for use to be uploaded onto website.

2023/81: Ivermectin – Increased number of scabies outbreaks that are resistant to permethrin. Likely to require more use of Ivermectin. HR has explored the option of supplying via IMOT but it's not viable. JV to explore community pharmacy stock holding as an option.

2023/82: L&SC formulary - East CV omissions and L&SC formulary - East Lancs CV Anomalies – Submitted to LSCMMG.

2023/94: New Product Request

- a. **Acarizax®:** Requested by Mr Napoleon Charaklias, (ENT Consultant) to treat moderate to severe house dust mite allergic rhinitis in patients who have failed to respond to anti-allergy drugs, and house dust mite asthma not controlled by inhaled corticosteroids in patients with mild to severe house dust mite allergic rhinitis. Use of this drug was requested as specialist initiated and RED traffic Light. The drug is currently Black traffic light on ELMMB. Members felt any change to its availability needed be equitable across Lancashire it will be assigned as GREY traffic Light for further review by LSCMMG.

Resolved: To be sent to LSCMMG for review

GREY traffic Light

2023/95: Formulary Updates

- a. **Anakinra** (intravenous, off-label use) requested for use as per Clinical Commissioning Policy 2021: Anakinra for haemophagocytic lymphohistiocytosis for adults and children.

Approved- RED Traffic Light

- b. **Fexofenadine 30mg tablets** (Telfast®) requested to facilitate accurate dosing for children under 12 years of age.

Approved- GREEN Traffic Light

- c. **Duraphat 5000ppm toothpaste:** requested by Dr Alex Daly (Consultant in Restorative Dentistry) for dental care use in cancer patients (after head and neck cancer treatment). This in line with national and public health guidance and can have a significant impact on patients' quality of life.

Approved- AMBER Traffic Light on consultant request.

- d. **Docosahexaenoic acid 380 mg, Eicosapentaenoic acid 460 mg capsules (omega 3 tablets):** requested by obstetrics and gynaecology specialist pharmacist to conform with the Northwest Regional guideline that states the drug should be given to all women fitting the criteria for preterm birth prevention. There was a discussion about



potential numbers of patients affected and also questions regarding the contributors to the guidance.

It was felt more information was needed to help support the application and it should be referred to LSCMMG to ensure a consistent approach is taken across Lancashire.

Grey Traffic Light – Refer to LSCMMG

2023/96 LSCMMG Consultations – July 2023

None for July: no meeting in August

2023/97 LSCMMG Recommendations – June 2023

None available: LSCMMG website not updated since May 2023

Resolved: items acknowledged by ELMMB. Website will be updated accordingly.

2023/98 Other Items

Exparel (bupivacaine liposome injectable suspension). Mr Gill gave a detailed presentation demonstrating the impact of Exparel over the previous 12 months. This was conditionally approved for TAP block in laparoscopic general surgery in September 2022. The results demonstrated were extremely positive showing faster recovery time for patients and a reduction in the need for post-operative opioid analgesia.

The additional cost of the product was acknowledged but the clear benefits of its application were apparent.

Resolved: ELHT to explore further potential opportunities for the use of Exparel and consider the managed introduction of the product into practice.

2023/99 Other Items

Maximizing benefits with biosimilar drugs

National drive for best value. ELHT have set up a working group to look at opportunities and current usage of products. LR happy to support if primary care input is required.

2023/100 Other Items

LMWH Best Practice guideline update, V7.1 – an updated version was presented by VG.

Resolved: The document was acknowledged and will be uploaded to ELMMB

2023/101 NICE Guidance – June 2023

CG157 Atopic eczema in under 12s: diagnosis and management. **Updated** 7th June 2023

NG101 Early and locally advanced breast cancer: diagnosis and management. **Updated** 14th June 2023



2023/102 NICE Recommendations – June 2023

Brexucabtagene autoleucl for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over recommended as an option by **NICE TA893**.

NHS England Commissioned Cancer Drug Fund **Traffic Light RED**

Axicabtagene ciloleucl for treating relapsed or refractory follicular lymphoma is not recommended by NICE TA894.

NHS England Commissioned **Traffic Light BLACK**

Axicabtagene ciloleucl for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy recommended as an option by NICE TA895

NHS England Commissioned Cancer Drug Fund **Traffic Light RED**

Bulevirtide for treating chronic hepatitis D recommended as an option by NICE TA896

NHS England Commissioned **Traffic Light RED**

Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma recommended as an option by NICE TA897 (updates and replaces TA573)

NHS England Commissioned **Traffic Light RED**

Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer recommended as an option by NICE TA898 (updates and replaces TA564)

NHS England Commissioned **Traffic Light RED**

Esketamine for treating major depressive disorder in adults at imminent risk of suicide is not recommended by NICE TA899

Terminated appraisal **Traffic Light BLACK**

Tixagevimab plus cilgavimab for preventing COVID-19 is not recommended by NICE TA900

Traffic Light BLACK

Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) not recommended by NICE TA901

Terminated appraisal **Traffic Light BLACK**

Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction is recommended as an option by NICE TA902.

ICB Commissioned **Traffic Light AMBER**

Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer is recommended as an option by NICE TA903

NHS England Commissioned **Traffic Light RED**

Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer is recommended as an option by NICE TA904

NHS England Commissioned **Traffic Light RED**

Upadacitinib for previously treated moderately to severely active Crohn's disease is recommended as an option by NICE TA905

ICB Commissioned, Blueteq required **Traffic Light RED**



Deucravacitinib for treating moderate to severe plaque psoriasis is recommended as an option by NICE TA907.

ICB Commissioned, Blueteq required

Traffic Light RED

2023/103 NICE Highly Specialised Technologies – June 2023

None this month

2023/104 EAMS (Early access to medicines scheme) – June 2023

None this month

Standing Items:

2023/105 For Action/Information: Lancashire & South Cumbria Medicines Management Group (LSCMMG)

LSCMMG-minutes-draft 08.06.2023

Resolved: acknowledged

2023/106 For Action/Information: Lancashire & South Cumbria FT Drugs and Therapeutics Committee

None – next meeting 20th July 2023

2023/107 For Action/Information: Antimicrobial Stewardship Committee (ASC)

March 2023 minutes (April and May Meetings cancelled)

June 2023 minutes not available. July meeting postponed.

Resolved: Match minutes acknowledged

DATE OF NEXT MEETING – Wednesday 20th September 2023 12.30pm via ‘Microsoft Teams’



**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

July 2023

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2021/101b	ELMMB Membership A review will be required to decide how ELMMB links with the ICS and ICB in the future and the policy for introduction of new drugs will require review as a result of that. New stakeholders to be considered. Await full ICB structure. ELMMB Terms of reference to be reviewed to reflect future meetings.	LR/VG/AB/HR	October 23
2023/81	Ivermectin JV to explore community pharmacy stock holding.	JV	September 23